

112441

DATE: November 13, 2025

TO: Board of Acquisition and Contract

FROM: Sherlita Amler, M.D.
Commissioner of Health

RE: Authorization to Enter into an Agreement with Laboratory Corporation of America Holdings to Provide Various Laboratory Testing Services for Clinic Patients of the Westchester County Department of Health's Tuberculosis (TB) and Sexually Transmitted Infections (STIs) Programs, for the Period from 12/01/25 to 11/30/30, in the total Not-to-Exceed Amount of \$400,000 payable per the test rates in Schedule A of the Agreement

The County of Westchester, acting by and through its Department of Health ("WCDH"), requests authorization to enter into an agreement with Laboratory Corporation of America Holdings ("LabCorp") to provide various laboratory testing services for clinic patients of the WCDH's Tuberculosis ("TB") and Sexually Transmitted Infections ("STIs") programs, for the period from 12/01/2025 to 11/30/2030, in the total not-to-exceed amount of \$400,000 payable per the test rates in Schedule "A" of the Agreement. The WCDH will bill those patients who have insurance to recoup some of the costs. The rates will remain fixed for the duration of the contract term.

As mandated by the New York State Department of Health and Public Health Law, the WCDH provides TB and STI health services at its district office clinics located in Yonkers and White Plains. Laboratory testing is required for the proper medical management of these patients in order to confirm a diagnosis and monitor treatment for both its efficacy and side effects. The Department of Labs and Research does not provide these specific lab tests.

In addition, since there was a change in NYS Public Health Law in 2014 pertaining to Article 28 licensed diagnostic and treatment facilities, of which the WCDH is one, laboratory testing services also include Hepatitis C virus screening and confirmatory testing, and other STI testing as necessary, which are provided to both TB and STI clinic patients according to NYSDOH guidelines to expand our standard of medical care.

Continuing with past changes in clinician practices regarding the confirmation of diagnosis, monitoring and treatment of TB, a more sensitive and clinically accurate test is used when medically indicated.

WCDH currently contracts with LabCorp and continuing the ongoing contractual arrangement would greatly minimize the disruption to patient services and clinic operations involved in changing to a new laboratory provider. From early on, the WCDH and LabCorp have worked to create a bi-directional electronic health data sharing interface between LabCorp's electronic lab test order and reporting system and the WCDH's web-based electronic health, case management, billing and reporting software. The successful implementation of this interface has contributed to streamlining clinic services and creating operational efficiencies, such as reducing the chance of ordering unnecessary or duplicate lab tests and receiving out-of-range test results more timely.

The public purpose is to promote the public health and general welfare of County residents by ensuring that proper courses of treatment for TB and STI screenings are provided to WCDH patients, and to their contacts who may have already been exposed. The goal is to properly screen, treat and monitor patients with both newly identified and active TB and STI cases through the provision of specific laboratory tests to control and prevent the spread of TB and STIs to minimize the public health risks, and improve patients' overall well-being.

The WCDH monitors and tracks the management of patients with TB, STIs, Hepatitis C and other blood-borne pathogens (Hepatitis B and HIV) through the analyses of test results and physicians' review of WCDH clinic program reports on an as-needed and monthly basis.

From January 2025 to date, approximately 2300 lab tests were done representing 739 patients who have been evaluated and treated for potential TB, STIs, Hepatitis C and other blood-borne pathogens (Hepatitis B and HIV) exposure and infection.

This contract would be exempt from the Westchester County Procurement Policy under Section 3 (a) (viii) - contracts for medical or health-related services.

Accordingly, the WCDH requests authorization to enter into a five-year contract with LabCorp for the various tests to be provided payable per the test rates in Schedule "A" of the Agreement.

Approval of the attached resolution is respectfully requested.

/dc
Attachment

RESOLUTION

RESOLVED, that the County of Westchester, acting by and through its Department of Health, ("WCDH"), is authorized to enter into an agreement with Laboratory Corporation of America Holdings to provide various laboratory testing services for clinic patients of the WCDH's Tuberculosis ("TB") and Sexually Transmitted Infections ("STIs") programs, for the period from 12/01/2025 to 11/30/2030, in the total not-to-exceed amount of \$400,000 payable per the test rates in Schedule A of the Agreement; and, be it further

RESOLVED, that the rates will remain fixed for the duration of the term; and, be it further

RESOLVED, that this Agreement is subject to County Appropriations; and, be it further

RESOLVED, that this Agreement is also subject to further financial analysis of the impact of any New York State Budget (the "State Budget") proposed and adopted during the term of this Agreement. The County shall retain the right, upon the occurrence of any release by the Governor of a proposed State Budget and/or the adoption of a State Budget or any amendments thereto, and for a reasonable period of time after such release(s) or adoption(s), to conduct an analysis of the impacts of any such State Budget on County finances. After such analysis, the County shall retain the right to either terminate this Agreement or to renegotiate the amounts and rates approved herein. If the County subsequently offers to pay a reduced amount to the Contractor, then the Contractor shall have the right to terminate this Agreement upon reasonable prior written notice; and, be it further

RESOLVED, that the County Executive or his duly authorized designee be and hereby is authorized and empowered to execute all appropriate contracts or documents necessary to effectuate the purposes of this resolution in the manner prescribed by law.

Department of Health
County of Westchester

Original Agreement	\$
First Amendment	\$
This Amendment	\$ _____
TOTAL	\$

Agreement #

Account to be
Charged/Credited

Fund	Dept	Major Program, Program & Phase or Unit	Object/ Sub-Object	Trust Account	Dollars	Year
101	27	0010 - HSSN	5200-4238-04		\$3,333	2025 (Dec)
101	27	0010 – HSSN	5000-4380-04		\$3,333	2025 (Dec)
101	27	0010 - HSSN	5200-4238-04		\$40,000	2026
101	27	0010 – HSSN	5000-4380-04		\$40,000	2026
101	27	0010 - HSSN	5200-4238-04		\$40,000	2027
101	27	0010 - HSSN	5000-4380-04		\$40,000	2027
101	27	0010 - HSSN	5200-4238-04		\$40,000	2028
101	27	0010 – HSSN	5000-4380-04		\$40,000	2028
101	27	0010 - HSSN	5200-4238-04		\$40,000	2029
101	27	0010 – HSSN	5000-4380-04		\$40,000	2029
101	27	0010 - HSSN	5200-4238-04		\$36,667	2030 (Jan – Nov)
101	27	0010 – HSSN	5000-4380-04		\$36,667	2030 (Jan – Nov)

Budget Funding Year(s)

(must match resolution) 2025-2030 Start Date 12/01/2025 End Date 11/30/2030

Funding Source	Tax	
	Dollars	<u>256,000</u>
	State Aid	<u>144,000</u>
\$ 400,000	Federal Aid	<u></u>
(must match resolution)	Other	<u></u>

SCHEDULE A

CBK	Test #	Test Name	Price
	000455	Thyroid Panel	\$25.72
1RM8	000810	Vitamin B12 and Folate	\$33.62
	001057	Uric Acid	\$11.34
1RM8	001099	Bilirubin, Total	\$5.25
	001214	Bilirubin, Total/Direct, Serum	\$11.55
	001321	Iron and TIBC	\$22.68
	001362	Creatine Kinase,Total	\$11.34
	001396	Amylase	\$15.64
	001404	Lipase	\$15.64
1RM8	001453	Hemoglobin A1c	\$10.51
1RM8	001537	Magnesium	\$6.30
	001958	GGT	\$11.34
1RM8	003038	Urinalysis, Routine	\$7.35
	003772	Urinalysis, Complete	\$10.92
	004416	hCG,Beta Subunit, Qnt	\$42.00
1RM8	004556	hCG,Beta Subunit,Qual	\$36.77
	004598	Ferritin	\$26.36
1RM8	005009	CBC With Differential/Platelet	\$3.16
	005013	CBC with Diff, Platelet, NLR	\$10.82
1RM8	005215	Sedimentation Rate-Westergren	\$6.30
1RM8	005280	Reticulocyte Count	\$6.30
	006072	RPR	\$11.55
	006395	Hep B Surface Ab, Qual	\$29.50
	006478	Toxoplasma gondii Ab, IgG	\$76.91
	006510	HBsAg Screen	\$24.99
	006627	C-Reactive Protein, Quant	\$26.46
	006718	Hep B Core Ab, Tot	\$32.55
	006726	Hep A Ab, Total	\$30.87
	006734	Hep A Ab, IgM	\$32.44
	007419	Carbamazepine(Tegretol),S	\$41.26
1RM8	007625	Lead, Blood (Adult)	\$24.89
	007823	Phenobarbital, Serum	\$36.22
	008128	GC Culture Only	\$39.11
1RM8	008847	Urine Culture, Routine	\$21.01
	012005	RPR, Rfx Qn RPR/Confirm TP	\$11.55
1RM8	020321	PT and PTT	\$22.06
	024778	BUN+Creat	\$11.55
	027011	Thyroid Profile II	\$100.59
	081950	Vitamin D, 25-Hydroxy	\$238.35
	082345	T pallidum Screening Cascade	\$36.96
	082370	Treponema pallidum Antibodies	\$36.96
	083935	HIV Ab/p24 Ag with Reflex	\$147.00
	083940	HIV 1/2 Ab Differentiation	\$273.00
	096776	Varicella-Zoster Ab, IgM	\$98.18
	126748	HAVIgM	\$32.44
	144000	Acute Hepatitis	\$339.15
1RM8	144050	HCV Antibody RFX to Quant PCR	\$13.61
1RM8	144127	HCV Antibody Cascade(PCR/Geno)	\$13.61

CBK	Test #	Test Name	Price
1RM8	144445	HAV, HBV, HCV	\$50.94
	161810	Anticardiolipin Ab, IgG, Qn	\$119.96
	164855	Antinuclear Ab by Multiplex	\$29.08
1RM8	180025	M genitalium NAA, Urine	\$38.56
1RM8	180039	NuSwab Vaginitis (VG)	\$248.88
1RM8	180051	Ct, Ng, Mycoplasmas NAA, Urine	\$150.00
	180060	Bacterial Vaginosis, NAA	\$283.50
1RM8	180084	M genitalium NAA, Urine w/Rflx	\$38.56
	180088	M gen Macrolide Resistance	\$397.00
1RM8	180098	Chlamydia/GC Amplification	\$92.82
1RM8	182879	QuantiFERON-TB Gold Plus	\$66.30
1RM8	182893	QFT-TB Plus (Client Incubated)	\$56.10
1RM8	182913	QuantiFERON-TB Gold Plus	\$66.30
1RM8	183194	Chlamydia/GC Amplification	\$92.82
1RM8	183616	Chlamydia/GC NAA, Confirmation	\$92.82
1RM8	186200	Ct/Ng, Client Prequot, NAA	\$92.82
1RM8	186211	Chlamydia Prequot, NAA	\$44.37
1RM8	186212	Gonococcus Prequot, NAA	\$48.45
1RM8	188078	Chlamydia trachomatis, NAA	\$44.37
1RM8	188086	Neisseria gonorrhoeae, NAA	\$48.45
1RM8	188672	Ct/GC NAA, Rectal	\$92.82
1RM8	188698	Ct/GC NAA, Pharyngeal	\$92.82
1RM8	188706	Ct NAA, Rectal	\$44.37
1RM8	188714	Ct NAA, Pharyngeal	\$44.37
1RM8	188730	GC NAA, Rectal	\$48.45
1RM8	188748	GC NAA, Pharyngeal	\$48.45
1RM8	204919	TP+TSH+T3+T4F	\$34.68
1RM8	217031	CMP14+7AC	\$7.35
	221010	Lipid Panel w/ Chol/HDL Ratio	\$32.34
	235010	Lipid Panel With LDL/HDL Ratio	\$32.34
1RM8	294174	AIP+ALT+AST+DBili+GGT+LD+TBili	\$5.78
	300862	HP5	\$135.71
	303755	Hepatic Function Panel (6)	\$12.39
	303756	Lipid Panel	\$32.34
	303758	Basic Metabolic Panel (7)	\$12.60
	322000	Comp. Metabolic Panel (14)	\$14.00
1RM8	322755	Hepatic Function Panel (7)	\$5.78
	322758	Basic Metabolic Panel (8)	\$12.81
1RM8	324741	Fe+TIBC+Fer	\$36.77
1RM8	333450	UA+Urine Culture	\$27.00
	501270	Hemoglobin A1c	\$53.29
	502226	Hb A1c+GlycoMark(R)(1,5 AG)	\$132.04
1RM8	505008	Helper T-Lymph-CD4	\$42.02
1RM8	550080	HCV RT-PCR, Quant (Non-Graph)	\$173.40
1RM8	550362	HCV RT-PCR, Quant (Non-Graph)	\$173.40
	550432	RNA, PCR (NonGraph) rfx/Geno	\$405.30
	551610	HBV Real-Time PCR, Quant	\$546.79
1RM8	700433	Lead, Maternal Blood	\$24.89
1RM8	717009	Lead, Blood (Pediatric)	\$24.89

CBK	Test #	Test Name	Price
1RM8	717016	Lead, Blood (Peds) Capillary	\$24.89
1RM8	977709	CBC/Diff Ambiguous Default	\$3.16
1RM8	998085	Venipuncture	\$9.09
1RM8	998205	Vendor Phlebotomy Fee	\$9.09
	S00001	Sensitivity Organism #1	\$73.50